Cargando…

Long-term decitabine/retinoic acid maintenance treatment in an elderly sAML patient with high-risk genetics

Elderly patients with AML ineligible for induction have a dismal prognosis; hence disease stabilization is a primary treatment goal. This case of a 75-year-old patient with secondary AML receiving the combination of decitabine and ATRA (within the DECIDER trial, NCT00867672) demonstrates an above-av...

Descripción completa

Detalles Bibliográficos
Autores principales:	Javorniczky, Nora Rebeka, Grishina, Olga, Hund, Inga, Pantic, Milena, Pfeifer, Dietmar, Schmoor, Claudia, Thomas, Johanna, Duyster, Justus, Becker, Heiko, Lübbert, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10683313/ https://www.ncbi.nlm.nih.gov/pubmed/38012682 http://dx.doi.org/10.1186/s13148-023-01596-5

Ejemplares similares

The antileukemic activity of decitabine upon PML/RARA-negative AML blasts is supported by all-trans retinoic acid: in vitro and in vivo evidence for cooperation
por: Meier, Ruth, et al.
Publicado: (2022)

Targeting cistrome and dysregulated transcriptome of post-MPN sAML
por: Verstovsek, Srdan, et al.
Publicado: (2017)

Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia
por: Becker, Heiko, et al.
Publicado: (2020)

Factors associated with the number and size of renal angiomyolipomas in sporadic angiomyolipoma (sAML): a study of adult patients with sAML managed in a Dutch tertiary referral center
por: Ruud Bosch, J. L. H., et al.
Publicado: (2018)

Biglycan as a mediator of proinflammatory response and target for MDS and sAML therapy
por: Vaxevanis, Christoforos K., et al.
Publicado: (2022)

Activity of decitabine combined with all-trans retinoic acid in oligoblastic acute myeloid leukemia: results from a randomized 2x2 phase II trial (DECIDER)
por: Rummelt, Christoph, et al.
Publicado: (2023)

DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acute myeloid leukemia who are ineligible for induction chemotherapy
por: Grishina, Olga, et al.
Publicado: (2015)

First-in-human study of WT1 recombinant protein vaccination in elderly patients with AML in remission: a single-center experience
por: Kreutmair, Stefanie, et al.
Publicado: (2022)

The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells
por: Greve, Gabriele, et al.
Publicado: (2015)

Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
por: Shoumariyeh, Khalid, et al.
Publicado: (2021)

Therapeutic effect of TRC105 and decitabine combination in AML xenografts
por: Baik, June, et al.
Publicado: (2020)

Recurrent transcriptional responses in AML and MDS patients treated with decitabine
por: Upadhyay, Pawan, et al.
Publicado: (2022)

Water pipe smoking as a cause of secondary erythrocytosis
por: Javorniczky, Nora Rebeka, et al.
Publicado: (2019)

Decitabine enhances targeting of AML cells by NY-ESO-1-specific TCR-T cells and promotes the maintenance of effector function and the memory phenotype
por: Kang, Synat, et al.
Publicado: (2022)

Reciprocal regulation of TWIST1 and OGT determines the decitabine efficacy in MDS/AML
por: Li, Hongjiao, et al.
Publicado: (2023)

P1345: EFFECT OF DECITABINE ON MACROPHAGE PHENOTYPE AND FUNCTION IN VITRO IN THE CONTEXT OF AML
por: Hilberink, Jacobien, et al.
Publicado: (2023)

Enabling Secure XMPP Communications in Federated IoT Clouds Through XEP 0027 and SAML/SASL SSO
por: Celesti, Antonio, et al.
Publicado: (2017)

A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML
por: Gore, Lia, et al.
Publicado: (2017)

Synchronous AML and pancreatic neuroendocrine neoplasm, both successfully treated with somatostatin analogs and decitabine
por: Ehsanullah, Syed, et al.
Publicado: (2022)

The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia
por: Santini, Valeria, et al.
Publicado: (2021)

Maintenance Therapy in AML
por: Reville, Patrick K., et al.
Publicado: (2021)

Epigenetic Priming of AML Blasts for All-trans Retinoic Acid-Induced Differentiation by the HDAC Class-I Selective Inhibitor Entinostat
por: Blagitko-Dorfs, Nadja, et al.
Publicado: (2013)

Absence of early platelet increment in healthy mice during decitabine treatment
por: Baumann, Juliane, et al.
Publicado: (2022)

Solving Identity Management in Modern Applications: Demystifying OAuth 2.0, OpenID Connect, and SAML 2.0
por: Wilson, Yvonne
Publicado: (2019)

Securing Web services with WS-Security: demystifying WS-Security, WS-Policy, SAML, XML Signature, and XML Encryption
por: Rosenberg, Jonathan B, et al.
Publicado: (2004)

Molecular Genetic Characterization of Individual Cancer Cells Isolated via Single-Cell Printing
por: Riba, Julian, et al.
Publicado: (2016)

Rapid and robust reversion to essential thrombocythemia on treatment with Decitabine in a case of hydroxyurea‐induced t‐MDS/AML
por: Horton, Joshua D., et al.
Publicado: (2015)

Multi‐dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML
por: Zhao, Chenchen, et al.
Publicado: (2019)

Synergistic inhibitory effects of low-dose decitabine in combination with bortezomib in the AML cell line Kasumi-1
por: Mpakou, Vassiliki, et al.
Publicado: (2021)

A phase II trial of decitabine, bortezomib and pegylated liposomal doxorubicin for the treatment of relapsed or refractory AML
por: Jonas, Brian A., et al.
Publicado: (2023)

Long-term response in refractory AML following azacitidine-failed MDS by salvage decitabine-bridged allogenic transplantation
por: Niscola, Pasquale, et al.
Publicado: (2019)

Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine
por: Hilberink, Jacobien R., et al.
Publicado: (2023)

Maintenance of elderly AML patients with androgens
por: Pigneux, Arnaud, et al.
Publicado: (2017)

Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia
por: Senapati, Jayastu, et al.
Publicado: (2022)

Decitabine combined with all-trans retinoic acid as treatment in a case of primary myelofibrosis transforming into acute myeloid leukaemia
por: Lin, Yan, et al.
Publicado: (2019)

Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivo
por: Schnerch, Dominik, et al.
Publicado: (2017)

Clinical Results of Hypomethylating Agents in AML Treatment
por: Cruijsen, Marjan, et al.
Publicado: (2014)

Maintenance therapy for AML after allogeneic HCT
por: Nayak, Rahul K., et al.
Publicado: (2022)

Validated single-tube multiparameter flow cytometry approach for the assessment of minimal residual disease in multiple myeloma
por: Dold, Sandra Maria, et al.
Publicado: (2020)

Quantitative determination of decitabine incorporation into DNA and its effect on mutation rates in human cancer cells
por: Öz, Simin, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_qodvbc6cpm39lkd5k67hcal4c8